Literature DB >> 21860040

Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis.

Andreas Bechdolf1, Hendrik Müller, Hartmut Stützer, Michael Wagner, Wolfgang Maier, Marion Lautenschlager, Andreas Heinz, Walter de Millas, Birgit Janssen, Wolfgang Gaebel, Tanja Maria Michel, Frank Schneider, Martin Lambert, Dieter Naber, Martin Brüne, Seza Krüger-Özgürdal, Thomas Wobrock, Michael Riedel, Joachim Klosterkötter.   

Abstract

Antipsychotics, cognitive behavioral therapy (CBT), and omega-3-fatty acids have been found superior to control conditions as regards prevention of psychosis in people at-risk of first-episode psychosis. However, no large-scale trial evaluating the differential efficacy of CBT and antipsychotics has been performed yet. In PREVENT, we evaluate CBT, aripiprazole, and clinical management (CM) as well as placebo and CM for the prevention of psychosis in a randomized, double-blind, placebo-controlled trial with regard to the antipsychotic intervention and a randomized controlled trial with regard to the CBT intervention with blinded ratings. The hypotheses are first that CBT and aripiprazole and CM are superior to placebo and CM and second that CBT is not inferior to aripiprazole and CM combined. The primary outcome is transition to psychosis. By November 2010, 156 patients were recruited into the trial. The subjects were substantially functionally compromised (Social and Occupational Functioning Assessment Scale mean score 52.5) and 78.3% presented with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition axis I comorbid diagnosis. Prior to randomization, 51.5% of the participants preferred to be randomized into the CBT arm, whereas only 12.9% preferred pharmacological treatment. First, assessments of audiotaped treatment sessions confirmed the application of CBT-specific skills in the CBT condition and the absence of those in CM. The overall quality rating of the CBT techniques applied in the CBT condition was good. When the final results of the trial are available, PREVENT will substantially expand the current limited evidence base for best clinical practice in people at-risk (prodromal) of first-episode psychosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21860040      PMCID: PMC3160113          DOI: 10.1093/schbul/sbr083

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  49 in total

1.  A cognitive model of the positive symptoms of psychosis.

Authors:  P A Garety; E Kuipers; D Fowler; D Freeman; P E Bebbington
Journal:  Psychol Med       Date:  2001-02       Impact factor: 7.723

2.  Preventing progression to first-episode psychosis in early initial prodromal states.

Authors:  A Bechdolf; M Wagner; S Ruhrmann; S Harrigan; V Putzfeld; R Pukrop; A Brockhaus-Dumke; J Berning; B Janssen; P Decker; R Bottlender; K Maurer; H-J Möller; W Gaebel; H Häfner; W Maier; J Klosterkötter
Journal:  Br J Psychiatry       Date:  2011-11-10       Impact factor: 9.319

3.  Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness.

Authors:  Antonio Preti; Matteo Cella
Journal:  Schizophr Res       Date:  2010-08-21       Impact factor: 4.939

Review 4.  Prospective investigations of the prodromal state of schizophrenia: review of studies.

Authors:  K A Olsen; B Rosenbaum
Journal:  Acta Psychiatr Scand       Date:  2006-04       Impact factor: 6.392

5.  Axis-I disorders and vulnerability to psychosis.

Authors:  Tanja Svirskis; Jyrki Korkeila; Markus Heinimaa; Jukka Huttunen; Tuula Ilonen; Terja Ristkari; Thomas McGlashan; Raimo K R Salokangas
Journal:  Schizophr Res       Date:  2004-12-02       Impact factor: 4.939

6.  Diagnosing schizophrenia in the initial prodromal phase.

Authors:  J Klosterkötter; M Hellmich; E M Steinmeyer; F Schultze-Lutter
Journal:  Arch Gen Psychiatry       Date:  2001-02

7.  Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.

Authors:  G Paul Amminger; Miriam R Schäfer; Konstantinos Papageorgiou; Claudia M Klier; Sue M Cotton; Susan M Harrigan; Andrew Mackinnon; Patrick D McGorry; Gregor E Berger
Journal:  Arch Gen Psychiatry       Date:  2010-02

Review 8.  Intervention in individuals at ultra-high risk for psychosis: a review and future directions.

Authors:  Patrick D McGorry; Barnaby Nelson; G Paul Amminger; Andreas Bechdolf; Shona M Francey; Gregor Berger; Anita Riecher-Rössler; Joachim Klosterkötter; Stephan Ruhrmann; Frauke Schultze-Lutter; Merete Nordentoft; Ian Hickie; Philip McGuire; Michael Berk; Eric Y H Chen; Matcheri S Keshavan; Alison R Yung
Journal:  J Clin Psychiatry       Date:  2009-06-30       Impact factor: 4.384

9.  Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state.

Authors:  Hiroyuki Kobayashi; Keiko Morita; Kiyoaki Takeshi; Hiroki Koshikawa; Ryoko Yamazawa; Haruo Kashima; Masafumi Mizuno
Journal:  J Clin Psychopharmacol       Date:  2009-10       Impact factor: 3.153

10.  The "close-in" or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder.

Authors:  Patrick D McGorry; Alison R Yung; Lisa J Phillips
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

View more
  25 in total

1.  Prediction and prevention of schizophrenia: what has been achieved and where to go next?

Authors:  Joachim Klosterkötter; Frauke Schultze-Lutter; Andreas Bechdolf; Stephan Ruhrmann
Journal:  World Psychiatry       Date:  2011-10       Impact factor: 49.548

2.  [Should antipsychotics be used in prodromal stages of schizophrenia to prevent psychosis? Con].

Authors:  A Bechdolf; S Laier; M Kallenbach; A Biester; K Leopold
Journal:  Nervenarzt       Date:  2015-11       Impact factor: 1.214

3.  [Prevention of psychotic disorders].

Authors:  J Klosterkötter
Journal:  Nervenarzt       Date:  2013-11       Impact factor: 1.214

4.  [Services for the early recognition of psychoses and bipolar disorders in Germany: inventory survey study].

Authors:  K Leopold; A Nikolaides; M Bauer; A Bechdolf; C U Correll; F Jessen; G Juckel; A Karow; M Lambert; J Klosterkötter; S Ruhrmann; S Pfeiffer; A Pfennig
Journal:  Nervenarzt       Date:  2015-03       Impact factor: 1.214

5.  The importance of cognitive processes for the integrative treatment of persons with schizophrenia.

Authors:  Mario Pfammatter; Hans Dieter Brenner; Ulrich Martin Junghan; Wolfgang Tschacher
Journal:  Schizophr Bull       Date:  2011-09       Impact factor: 9.306

Review 6.  Evidence-based psychotherapy for the prevention and treatment of first-episode psychosis.

Authors:  Hendrik Müller; Sonja Laier; Andreas Bechdolf
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-27       Impact factor: 5.270

7.  [Early recognition and intervention for bipolar disorders: state of research and perspectives].

Authors:  A Pfennig; C U Correll; K Leopold; G Juckel; M Bauer
Journal:  Nervenarzt       Date:  2012-07       Impact factor: 1.214

8.  The usefulness for indicated prevention of severe mental disorders should play a central part in the further development of CBT.

Authors:  Joachim Klosterkötter
Journal:  World Psychiatry       Date:  2014-10       Impact factor: 49.548

9.  Prediction and prevention of psychosis: current progress and future tasks.

Authors:  Stephan Ruhrmann; Frauke Schultze-Lutter; Stefanie J Schmidt; Nathalie Kaiser; Joachim Klosterkötter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-26       Impact factor: 5.270

Review 10.  [Prediction of psychoses].

Authors:  J Klosterkötter
Journal:  Nervenarzt       Date:  2014-10       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.